A pioneer of human-centered innovation, Maryne Cotty-Eslous stands at the crossroads of the digital and the biological in Dubai, embodying a singular vision: innovation as an act of resilience and humanity.
At just 35 years old, she holds a leading position in the global health tech landscape and in the world of neurodiverse entrepreneurship. As the founder of several companies, she has revolutionized chronic pain management through nonpharmacological digital therapies, all grounded in a transdisciplinary philosophy.
She is a rare figure – a neuroscientist working at the intersection of artificial intelligence, cognitive science, and deep humanism – turning trauma and neurodivergence into powerful catalysts for change.
“Being an entrepreneur never was a dream for me, but it always was my nature,” she tells us.
On December 21, 2005, at exactly 7:30 p.m., a wall of concrete brought her heart to a sudden halt. The car crash, at over 150 km/h, became the first defining moment in her life. “My body screamed… every sound was unbearable.” Doctors later told her, “You’re very lucky, miss. You should have died.” That trauma marked the beginning of a lifelong mission: to understand and heal the living.
Later diagnoses – including endometriosis and Ehlers-Danlos syndrome – would reveal an invisible neurodivergence. Her struggles in school were never a sign of incapacity, but rather a different cognitive profile she would soon learn to embrace and transform into a strength. Over the years, she earned nine degrees across anthropology, neuroscience, and artificial intelligence. In her view, innovation is never improvised – it is born from the productive collision of knowledge streams.
In 2024, now based in Dubai, she founded MCE Corp, a holding group that brings together several complementary ventures in consulting, neurotechnology, digital health, and support ecosystems for atypical thinkers. For her, entrepreneurship is not an aspirational career path – it is intrinsic.
She transforms failure into a renewed attempt, each time more aligned with her deeper purpose: inventing a model of care that places the human being – in all dimensions – at its center.
Among her flagship breakthroughs is her discovery of alternative, non-drug-based solutions for managing chronic pain. By combining AI-calibrated visual and auditory stimulation, she aims to deliver neurophysiological regulation without the side effects associated with conventional medicine.
At the core of her current work lies one of her most inclusive commitments: a coaching and mentoring program dedicated to neurodivergent entrepreneurs, based on the belief that 15 to 20 percent of the world’s population thinks differently – a vast reservoir of creativity largely untapped in the professional world. Through this initiative, Maryne offers training, access to community, and strategic tools to convert cognitive uniqueness into entrepreneurial power.
But it is in Dubai that her impact truly accelerates. Through NeuroCare, a proprietary device she is developing, Maryne seeks to modulate the neural circuits associated with pain by using precise audio-visual frequency patterns. The objective is clear: to offer a non-invasive, drug-free therapy capable of significantly reducing the perception of pain within just a few weeks of use – an innovation set to be unveiled at GITEX Global once commercialized.
In February 2025, she received the prestigious Innovation Trophy at the French Middle East Trophies in Dubai, a recognition of her role as a bridge-builder between France and the UAE in the fields of AI and digital health. As she said at the time:
“This recognition highlights the work accomplished with my teams to push the boundaries of innovation and shape the technologies of tomorrow.”
This honor cemented her place within the upper echelons of international innovation. Her active role in ongoing debates around AI ethics, health data privacy, and digital regulation reflects a humanistic approach that puts the individual at the center of every technological leap. For Maryne, the value of a project is not measured in metrics or funding rounds, but in its ability to improve real lives in tangible ways.
Her scientific vision is rooted in a philosophy of perpetual movement. “If we stop moving, we wither away,” she recently shared in an interview. Every obstacle is, to her, an invitation to invent what does not yet exist. Every instance of pain is fertile ground for creation. This perspective encapsulates the essence of her work: innovation not as a product, but as a service to humanity. That is the very soul of NeuroCare.
At the intersection of applied neurotechnology and non-pharmacological therapeutic innovation, the NeuroCare project today represents the culmination of Maryne Cotty Eslous’s research and convictions. Designed as a next-generation medical solution, the device aims to selectively modulate the activity of neural circuits involved in the genesis and maintenance of chronic pain, through a fully non-invasive approach entirely free of any pharmacological agent.
Based on proprietary technology derived from over ten years of multidisciplinary research, NeuroCare relies on neurocognitive stimulation protocols that combine visual sequences, auditory rhythms, and synchronized vibratory signals, calibrated to the functional characteristics of the targeted neural networks.
The orchestration algorithm, built on an artificial intelligence engine, dynamically adjusts the intensity, duration, and frequency profile of the stimuli in response to the patient’s behavioral and physiological markers, in order to induce a sustained neuroplastic regulatory effect on nociceptive pathways.
This progressive neurobehavioral modulation enables the interruption of hyperalgesic feedback loops while preserving the integrity of sensory structures. In initial exploratory cohorts conducted in controlled clinical environments, a significant reduction in perceived pain intensity was observed as early as the third week of treatment, without adverse effects or cognitive maladaptation.
The ambition of NeuroCare is not merely to provide transient relief, but rather to initiate a functional reprogramming of cerebral circuits by acting on thalamo-cortical synchronization and abnormal gamma oscillations – patterns frequently identified in patients suffering from chronic pain syndromes.
In Dubai, she is investing in a strategic playing field – a global innovation hub hungry for disruption, where over EURO 50 billion have been allocated to AI development as part of a historic partnership with France. This ultra-connected environment, primed for high-speed scaling, is allowing NeuroCare to prepare for rapid deployment across hospitals and clinics in the UAE and beyond.
Today, Maryne Cotty-Eslous represents a new hybrid model: visionary entrepreneur, transdisciplinary innovator, inclusive mentor, and humanistic strategist. Her legacy is taking shape not only in the companies she builds, but also in the way she empowers atypical profiles, delivers technological responses to pain, and redefines the true meaning of impact. Her message to the next generation of creators is simple and powerful:
